{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-304880","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2026-07-15T20:46:28+00:00","discovered_at":"2026-07-15T20:47:00.435739+00:00","generated_at":"2026-07-15T20:47:20.210830+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aldeyra receives FDA Type A meeting minutes for reproxalap NDA; plans Type D meeting by Q3 2026","bullets":["Received minutes from Type A meeting with FDA on June 10, 2026 regarding reproxalap NDA for dry eye disease.","Requested clarification of the minutes from FDA on July 15, 2026.","Intends to request a Type D meeting to discuss potential resubmission of the NDA.","Type D meeting expected to be held by the end of the third quarter of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-304880","json":"https://secwatch.observer/filing/0001193125-26-304880.json","markdown":"https://secwatch.observer/filing/0001193125-26-304880.md","text":"https://secwatch.observer/filing/0001193125-26-304880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526304880/0001193125-26-304880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526304880/aldx-20260714.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-15T20:47:20.210830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}